Clinical trial setback shifts attention to Regeneron Pharmaceuticals pipeline

Regeneron Pharmaceuticals (REGN) is back in focus after disappointing clinical trial results for one of its pipeline drugs, which weighed on recent performance and pushed investor attention toward unmet development milestones.

At the same time, therapies Dupixent and Eylea remain key anchors for the business. Regeneron Pharmaceuticals has been repurchasing shares and avoiding value destructive acquisitions, a combination that shapes how investors are reassessing the stock today.

Over the past year, Regeneron Pharmaceuticals has combined a rising 1 year total shareholder return of 20.39% with a weaker year to date share price return of 15.48% and a 90 day share price decline of 12.97%. This suggests recent clinical trial disappointment has cooled momentum after a stronger prior period.

If trial news has you reassessing biotech risk and reward, it can help to compare across peers using a curated list of healthcare focused AI opportunities such as 40 healthcare AI stocks

After Regeneron Pharmaceuticals sold off on trial disappointment, the stock now trades well below both analyst targets and some intrinsic value estimates. This raises the question of where a reasonable fair value range actually sits versus today’s price.

Most Popular Narrative: 21.3% Undervalued

Against the last close at $656.12, the most followed narrative for Regeneron Pharmaceuticals points to a fair value of $833.31. This frames the recent pullback as a valuation gap driven more by revised expectations than by a broken business model.

Regeneron's broad and advancing pipeline including recent or upcoming pivotal data in immunology, oncology (notably Lynozyfic and odronextamab), genetic medicines, and obesity positions the company to benefit from demographic-driven increases in demand for advanced therapies and from the rise in personalized and precision medicine, supporting future revenue growth and pipeline-driven earnings upside.

Want to see what underpins that discount to fair value? The narrative leans on steady top line expansion, firmer margins, and a future earnings multiple below current sector levels. Curious how those pieces add up to the $833 mark?

The most widely followed narrative applies a 7.24% discount rate and builds in measured increases in revenue, profit margins and earnings per share, while still assuming Regeneron Pharmaceuticals trades on a future P/E below where many biotech peers sit today. It also factors in a gradual reduction in share count, which can lift earnings per share, and uses those projections to arrive at the $833.31 fair value.

Analysts behind this view expect mid single digit to low double digit annual revenue growth and profit expansion that together support earnings rising from about $4.4b today to a materially higher level by the late 2020s, with a P/E multiple in the mid teens applied to those future earnings. That combination, once discounted back using the 7.24% rate, yields a value that sits well above the current market price, even after recent clinical setbacks trimmed both growth and margin assumptions and nudged the fair value down from $875.31.

Result: Fair Value of $833.31 (UNDERVALUED)

However, Regeneron Pharmaceuticals still faces real pressure if Eylea competition intensifies or if higher R&D and manufacturing spend fails to translate into commercially successful pipeline assets.

Next Steps

With sentiment around Regeneron Pharmaceuticals mixed after the trial setback, it can be useful to look past headlines and weigh the full picture for yourself. If you want to see what investors are currently optimistic about, review the 4 key rewards

Looking for more Regeneron Pharmaceuticals style ideas?

If you stop at Regeneron Pharmaceuticals, you could miss other compelling setups, so put a few minutes into scanning fresh ideas before the next wave of headlines hits.

• Spot potential value gaps early by running through 44 high quality undervalued stocks, which combines solid fundamentals with prices that may not fully reflect them.
• Prioritize resilience in choppy markets by checking 79 resilient stocks with low risk scores, focused on companies with sturdier financial profiles and calmer trading histories.
• Get ahead of the crowd with screener containing 20 high quality undiscovered gems, highlighting quality stocks that many investors may not be watching yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.